US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Surge of new orders totalling 50,000 Euro signals new sales season for Inhalation Research Services

(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services, as the summer season comes to a close and the company and wider inhalation industry gear up for a busy second half of the year.The combined value of the new orders totals 50,000 Euro, or 600,000 SEK. The orders have been received from returning clients in ISAB’s extensive portfolio, primarily for CRO projects by its Inhaled Research Services team. ISAB CEO Manoush Masarrat: “we are pleased to see clients hit the ground running again following the

Inhalation Sciences presents at well-received FDA public workshop GDUFA

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.ISAB’s webinar session at the workshop was titled “Predictive Tools for Generic Product Development & Assessment”. It was held by ISAB CSO and Founder Per Gerde and ISAB’s Director of Projects Dr Maria Malmlöf. Engagement

Inhalation Sciences receives new order worth 60,000 Euro from long-term big pharma client

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.The order is for essential spare parts and consumables for the client’s PreciseInhale® system. The client is a long-term customer of ISAB’s with a world-class generics pipeline and robust R&D organisation. Prior to its purchase and installation of PreciseInhale® the client carried

Inhalation Sciences secures product service contract worth 47,000 Euro

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.The client is a long-standing ISAB customer. Its suite of in-house ISAB instruments has played an important role in developing its competitive and substantial pipeline of inhaled therapeutics. The new contract will cover the service and maintenance

Inhalation Sciences secures new order worth 54,700 Euro

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.Inhalation Sciences has received an order valued at 54,700 Euro with a new customer in Europe developing a generic inhaled drug-device combination therapy. The project will carry out required regulatory testing through a trusted service partner, sourced by ISAB, that

Inhalation Sciences signs collaboration agreement with leading Indian multinational pharma company

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.The company is ISAB’s first Indian client and is a highly agile, innovative multinational with a large number of development projects ongoing and a YoY R&D investment that has grown continuously over recent years. The Indian pharmaceutical industry as a whole is a

Inhalation Sciences wins new Purchase Order from Asian distributor worth 94,000 USD

Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, the second order from the region in a week. The order includes in vitro modules for inhaled drug development.ISAB has received a new order for its in vitro technology from a regional distributor in Asia worth 94,000 USD. It is the second order from the region in one week. Investment and innovation in inhaled therapies has increased significantly in Asia-Pacific over recent years. In September 2022, for example, China approved the world’s first inhaled

Inhalation Research Services wins new order worth 98,000 Euro from returning US customer

Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.The returning client is a midsize US pharma company developing inhaled therapies.

Inhalation Sciences receives new order worth 53,000 Euro from returning customer

Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client’s two existing PreciseInhale systems.The client is a loyal ISAB customer, with two PreciseInhale systems in place. The client’s team carry out advanced in vivo work on New Chemical Entities, using the highly accurate preclinical data generated by PreciseInhale to significantly reduce risk in the later clinical

Inhalation Sciences receives green light from the US FDA to start the experimental phase of FDA BAA dissolution research project

(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project, ISAB today announces that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company’s facilities in Sweden.The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt technology by comparing drug formulations, aimed for administration via inhalation, with

Inhalation Sciences provides comments on the start of 2023

2023 has started in line with our expectations and we continue to see a steady inflow of inquiries from various biopharma customers and good progress in ongoing collaborations. We look forward to a spring and summer represented by a high-level of customer activity including several value-creating activities to continue our growth projectory.The year has started off with a signed customer order of over SEK 900,000 from a new US customer who develops targeted antiviral therapies. This customer's first project will use ISAB's DissolvIt module to perform solubility tests, with the goal of

Inhalation Sciences receives IRS order worth 35,000 Euro from global generics company

Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) project. The client has chosen ISAB’s DissolvIt[®] for the project, due to its outstanding accuracy in testing generic formulations against originator products to define bioequivalence and, potentially, IVIVC (In Vitro In Vivo correlation), both critical metrics in generic drug development.The new client’s development team are highly expert and experienced in Pharmacokinetics (PK), bioequivalence and dissolution studies. They have chosen ISAB’s

Inhalation Sciences receives IRS order worth 118,464 Euro from US client following 50,000 Euro deposit

(Stockholm, Sweden, 7 March 2023) On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The client has now confirmed the entire IRS order, totaling 118,484 Euro (approx. 1.3 MSEK), of which 50,000 Euro has already been paid.A returning ISAB client, a mid-size US pharma company, has confirmed an IRS order worth 118,484 Euros in total following an advanced payment in February of 50,000 Euro. The client has chosen ISAB’s high-

Inhalation Sciences receives IRS order worth over 914,000 SEK from new US pharma customer

Inhalation Sciences AB (ISAB) has received an order worth over 914,000 SEK (81,200 Euros) for an Inhalation Research Service (IRS) project from a new US customer developing targeted antiviral therapies. In this first project they have chosen to use the DissolvIt[®] module to carry out dissolution testing, due to its exceptional accuracy which can reduce risk and attrition in later drug development.ISAB has received an order from a new customer, a cutting-edge US pharmaceutical company developing novel antiviral therapies to treat a range of viral diseases from influenza to COVID-19.

Join Inhalation Sciences’ CEO and Chairman for Outlook 2023 – post your questions now

(Stockholm, Sweden, 12 January 2023) Post your questions to ISAB CEO Manoush Masarrat and Chairman Daniel Spasic for their joint Redeye event on March 6[th], 2023. The pair will take investor’s questions on 2022’s development and milestones, and how ISAB will keep growing momentum in 2023. Please submit your questions by February 27[th], 2023.At 10.00 CET Match 6[th] 2023, ISAB CEO Manoush Masarrat and Chairman Daniel Spasic will present Inhalation Sciences’ 2022 company update and outlook for 2023. They will provide strategic and operational perspectives on ISAB’s development and

DDL2022: Inhalation Sciences had several landmark presentations at well-attended event

At this year’s DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical study of PreciseInhale, showing how the system out-performed commercial inhalers in targeting aerosols to specified regions of the lung. A second poster on ISAB’s in vitro simulation module DissolvIt was also presented. This was the first onsite DDL event since the end of European Covid-19 restrictions.DDL conferences (Drug Delivery to the Lungs) are some of the most well-attended events in the global inhalation industry’s calendar. As the first DDL

Inhalation Sciences begins planned FDA BAA dissolution research project

(Stockholm, 14 November 2022) In September 2022 Inhalation Sciences Sweden AB (ISAB) was awarded an FDA BAA (Broad Agency Announcement) contract for a research project evaluating the discriminative power of its DissolvIt[® ]in vitro dissolution technology. The project has now had its Kick-off meeting and is underway. ISAB has communicated previously on this project, most recently on 15 September 2022.The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt® technology by comparing drug formulations, aimed for administration via inhalation, with

Inhalation Sciences signs IRS order worth 1.17 million SEK with large generic pharma company

Inhalation Sciences has signed a new contract worth 1.17 million SEK (107,600 Euros) for an Inhalation Research Service (IRS) project aiming to establish differences in the dissolution profiles between a generic inhaled therapy and its reference drug – a key component of bioequivalence.Dissolution data are a crucial component of bioequivalence, a key requirement that  a generic drug needs to comply to for regulatory approval. Bioequivalence is particularly challenging to define for inhaled drugs - a fast-growing market segment that is forecast to grow from 17.5 BUSD (2021) to 38.45 BUSD by

Inhalation Research Services receives revised order with increased payment from US pharma company

(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client’s choice of IRS for research into a new repurposed drug being reformulated for

Inhalation Sciences submits abstract to present landmark data from PreciseInhale clinical study at DDL 2022

(Stockholm 19 July 2022) ISAB has submitted an abstract to present data from its study validating PreciseInhale for clinical use, at the Drug Delivery to the Lungs (DDL) conference 2022 in Edinburgh, Scotland. The data demonstrate that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. DDL is one of the inhalation markets’ most influential events, with all major companies within the industry set to be present onsite, for the first time post-pandemic.At DDL 2022, 7- 9 December in Edinburgh, Scotland,

Inhalation Sciences receives positive feedback from FDA, moves onto next stage of process to validate DissolvIt as FDA-recommended standard research method in US

(Stockholm, 5 May 2022) Inhalation Sciences (ISAB) has received positive feedback from the US FDA (Food and Drug Administration) on its white paper, previously communicated on 17 January 2022, that aims to validate the company’s DissolvIt[®] model as an FDA-recommended technology. ISAB has now been invited to submit a full proposal for its research project into DissolvIt[®]. If successful, the FDA will co-fund the project to the value of 250 KUSD (approx. 2.2 MSEK) annually for up to two years.As communicated on 17 January 2022, Inhalation Sciences submitted a formal whitepaper to the FDA’s

Inhalation Sciences AB signs new distribution agreement to cover China, Hong Kong and Macau

(Stockholm, Sverige, 12 April 2022) Inhalation Sciences AB has signed a new distribution with Quantaflux Industrial Co. Ltd that will cover the crucial China, Hong Kong and Macau markets. CEO Manoush Masarrat: “China is an important market for inhaled medicine, with robust R&D and a high level of local investment. We are delighted to be partnering With Quantaflux Industrial.”Quantaflux Industrial Co. Ltd is a Labtech distributor for lab testing instruments covering China, Hong Kong and Macau. The company has strong ties to China’s extensive network of inhalation drug R&D labs as a

Inhalation Sciences AB signs new distribution agreement with leading UK Labtech supplier

(Stockholm, Sverige, 11 April 2022) Inhalation Sciences AB has signed a new distribution agreement with Omicron Research Ltd, a leading supplier of dissolution instruments in the UK and Ireland. CEO Manoush Masarrat: “The UK is a key market with enormous potential. We welcome this new agreement.”Omicron Research Ltd has a robust customer base in the UK and Irish pharmaceutical industry as a leading supplier of dissolution, chromatography and spectroscopy instruments. The company began life as the sales branch of a manufacturer of dissolution systems for oral solid drugs. The addition of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe